Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Role of c-Myc in normal and leukemic human hematopoietic stem cells (HSCs)
EF 2013-14
Résumé
Background:
Current evidence indicates that both normal and leukemic human blood cell populations are sustained by very rare stem cells with unique phenotypes and proliferation control mechanisms. Interestingly, reproducible methods that support the production of either of these cell types outside the body have been difficult to devise. Nevertheless, achieving this goal remains important for many reasons. These include obtaining increased numbers of normal human blood stem cells to treat cancer patients or patients with a congenital deficiency requiring a transplant to rescue or replace their blood-forming systems with normal cells. A better understanding of mechanisms regulating the expansion of leukemic stem cells is also key to the rational development of future curative strategies for leukemia.
Approach:
MYC is a gene reported to play a role in controlling the behaviour of blood stem cells in mice and permanently immortalized cell lines. Expression of the MYC gene is also deregulated in many human cancers including leukemias. My project aims to determine whether forcing an elevated expression of MYC in primitive normal or preleukemic human cells can promote their abnormal expansion or progression to a more aggressive leukemic state. Forced overexpression of MYC will be achieved by infecting primitive cells with a virus engineered to introduce the MYC gene and a fluorescent reporter into the chromosomes of the infected cell. The effects of this manipulation on the cells produced by the infected cells both in vivo (in transplanted immunodeficient mice) and in cultures that sustain the long-term proliferation of maturing normal cells will then be examined. I will also test the effect of varying MYC levels on these endpoints.
Significance:
The information generated by this study will lead to an improved understanding of the mechanisms controlling blood stem cell expansion in a healthy or leukemic context. The potential applications of this research include the ability to obtain large numbers of blood stem cells in vitro for therapeutic purposes and the development of therapies for leukemia.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
311739
Name
Bulaeva Elizaveta
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Role of c-Myc in normal and leukemic human hematopoietic stem cells (HSCs)
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bone Marrow; C-Myc Overexpression; Cellular Differentiation; Hematology; Human Hematopoietic Stem Cell; In Vitro Stem Cell Expansion; Lentiviral Transduction; Leukemia; Self-Renewal; Umbilical Cord Blood
Abstract
Background:
Current evidence indicates that both normal and leukemic human blood cell populations are sustained by very rare stem cells with unique phenotypes and proliferation control mechanisms. Interestingly, reproducible methods that support the production of either of these cell types outside the body have been difficult to devise. Nevertheless, achieving this goal remains important for many reasons. These include obtaining increased numbers of normal human blood stem cells to treat cancer patients or patients with a congenital deficiency requiring a transplant to rescue or replace their blood-forming systems with normal cells. A better understanding of mechanisms regulating the expansion of leukemic stem cells is also key to the rational development of future curative strategies for leukemia.
Approach:
MYC is a gene reported to play a role in controlling the behaviour of blood stem cells in mice and permanently immortalized cell lines. Expression of the MYC gene is also deregulated in many human cancers including leukemias. My project aims to determine whether forcing an elevated expression of MYC in primitive normal or preleukemic human cells can promote their abnormal expansion or progression to a more aggressive leukemic state. Forced overexpression of MYC will be achieved by infecting primitive cells with a virus engineered to introduce the MYC gene and a fluorescent reporter into the chromosomes of the infected cell. The effects of this manipulation on the cells produced by the infected cells both in vivo (in transplanted immunodeficient mice) and in cultures that sustain the long-term proliferation of maturing normal cells will then be examined. I will also test the effect of varying MYC levels on these endpoints.
Significance:
The information generated by this study will lead to an improved understanding of the mechanisms controlling blood stem cell expansion in a healthy or leukemic context. The potential applications of this research include the ability to obtain large numbers of blood stem cells in vitro for therapeutic purposes and the development of therapies for leukemia.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Bulaeva, Elizaveta
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~